Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

The Importance of Indoor Air Quality

YourUpdateTV

Aire Serv®, a Neighborly® company, is a global franchise providing installation, maintenance and repair of heating, ventilation, air conditioning and indoor air quality systems. Aire Serv® franchisees provide services to residential and commercial customers from more than 200 locations worldwide. Established in 1992, Aire Serv® is part of Neighborly®, is the world’s largest home services franchisor of 29 brands and nearly 5,000 franchises collectively serving 10 million+ customers in nine countries, focused on repairing, maintaining and enhancing homes and businesses, united under one platform serving 10 million+ customers in nine countries. Neighborly® brands are found at Neighborly.com and through the Neighborly App. For more information about Aire Serv®, visit AireServ.com. The quality of the air we breathe has a direct effect on our health and comfort. You may notice some of the more prominent side effects of indoor air pollution, like an unpleasant odor, but many others go undetected. These include headaches, fatigue, respiratory issues, and other serious, long-term conditions. Recently, Hall of Famer and Super Bowl Champion, Jerome “The Bus” Bettis, teamed up with Aire Serv, a Neighborly company, on a nationwide satellite media tour to discuss the importance of indoor air quality, especially when it comes to how pollution can impact workouts. A video accompanying this announcement is available at: https://youtu.be/moFVmGsuRK0 Jerome was diagnosed with asthma at the age of 14 and as an avid athlete, making sure he wasn’t aggravating that condition was critical to his performance level. As a result, he started learning about different air pollutants and discovered that many are actually found within the home. When you’re constantly breathing in air pollutants, it can take a toll on your breathing over time and especially make it difficult to breathe deeply while exercising. When you don’t get enough oxygen, your energy level decreases, which directly impacts the intensity and performance of your workouts. The cleaner the air you breathe, the better you’re setting up your body for a successful training session. Something as simple as changing the air filters quarterly can have a great impact on indoor air quality. Also, being more mindful of the items in your household will help, such as opting for real plants that will help purify the air indoors, buying beeswax or organic candles, and even swapping out dryer sheets and fabric softeners for more natural alternatives. The experts at Aire Serv recommend making sure you have proper ventilation and filtration throughout the home, as well as air treatments to get rid of any bacteria or viruses. To determine what’s best for your home, call a service professional from Aire Serv to test for you, as this will eliminate a lot of the guesswork. Aire Serv service professionals will go through a discovery stage that discusses issues in the home such as dry throat, allergies, asthma, headaches, and fatigue before analyzing the air quality inside of the home. Once the analysis is complete, the service professionals can recommend additional measures to improve the quality of air in the home, including air and duct cleaning, duct sealing, UVC protection, and ionization. For more information, you can visit AireServ.com, or Neighborly.com to learn more about their other home service brands. About Jerome “The Bus” Bettis: The former Pittsburgh Steelers Running Back is one of the best all-time running backs in the NFL (6th overall in rushing). Jerome Bettis was also the recipient of the Walter Payton Man of the Year Award in 2001. “The Bus” finished his NFL career in January 2006 after 13 seasons, retiring immediately following the Pittsburgh Steelers’ 21-10 win over the Seattle Seahawks in Super Bowl XL in his hometown of Detroit. Diagnosed with asthma at age 14, Bettis is a tireless advocate for asthma education and awareness. Bettis founded and establish “The Bus Stops Here Foundation” in 1996 to help improve the quality of life for disadvantaged and underprivileged children. About Aire Serv ®: Aire Serv®, a Neighborly® company, is a global franchise providing installation, maintenance and repair of heating, ventilation, air conditioning and indoor air quality systems. Aire Serv® franchisees provide services to residential and commercial customers from more than 200 locations worldwide. Established in 1992, Aire Serv® is part of Neighborly®, is the world’s largest home services franchisor of 29 brands and nearly 5,000 franchises collectively serving 10 million+ customers in nine countries, focused on repairing, maintaining and enhancing homes and businesses, united under one platform serving 10 million+ customers in nine countries. Neighborly® brands are found at Neighborly.com and through the Neighborly App. For more information about Aire Serv®, visit AireServ.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 04, 2022 02:54 PM Eastern Standard Time

Video

Reaxys to enhance chemistry patents with patent provenance for greater competitive intelligence insights

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce its market leading position in chemistry patent coverage and the extension of its collaboration with LexisNexis® PatentSight®. In March 2021, Elsevier launched its initiative to strengthen the existing patent coverage in Reaxys ®. The content expansion resulted in a 15-fold increase in patent coverage and ensures pharma and chemical companies and their researchers do not miss key competitive intelligence insights. The number of discoverable patents in Reaxys now exceeds 30 million, and the Reaxys-PatentSight collaboration will further enhance content with the patents’ ownership information. These insights will enable companies to better understand competitors’ IP strategies, identify innovative players in a field and confidently assess the commercial viability of their projects. Marco Richter, Global Head of Product, LexisNexis Intellectual Property Solutions, said: “Competition is intense in R&D: With an increasingly diverse landscape of players in the pharmaceutical industry — from niche start-ups to emerging biotech companies, to academic research. To strengthen drug discovery capabilities and shorten development cycle, pharma companies often acquire specialized biotech companies or in-license drug candidates active in preclinical and clinical phases. “Keeping up with the latest information about competitor IP activity and new research is a business-critical challenge. We are pleased to be continuing our collaboration with Elsevier to provide companies with more extensive information on IP history and understand that getting new drugs to market is a resource-intensive process for researchers and know our content can help accelerate this.” The Reaxys updates will enhance competitive intelligence by distinguishing “current patent assignee” and “original patent assignee” to track ownership over time, demonstrating which companies are most prominent in a particular field. Easy-to-use search filters will allow users to sort between inventors and current patent holders. Further enhancements to the patent assignee ontology that unify different common and legal names for corporations will be released in 2022. This allows companies to avoid blind spots and stay on top of emerging competitors when assessing the competitive landscape for a technology. Dr. Ivan Krstic, Head of Chemistry Solutions at Elsevier added: “Reaxys users want to clearly view current and past patent holders. These upgrades are in response to their feedback, and underlines our commitment to addressing user needs and responding in a timely manner with significant enhancements to the content and user experience. Because of this virtuous cycle, Reaxys has become the patent discovery space for chemists in pharma and chemical companies. “This work underpins our vision to make Reaxys the most comprehensive, innovative and authoritative chemistry research information system that supports chemistry workflows and use cases, enabling the digital transformation that organizations need to achieve to help drive better research outcomes.” To find out more about the collaboration and patent coverage in Reaxys, visit the Reaxys website. --- About LexisNexis Legal & Professional LexisNexis® Legal & Professional is a leading global provider of legal, regulatory and business information and analytics that help customers increase productivity, improve decision-making and outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis ® and Nexis ® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,600 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. About LexisNexis Intellectual Property LexisNexis Intellectual Property brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations and ultimately achieve a competitive advantage for their business. Our suite of workflow and analytics solutions (LexisNexis ® IP Data Direct, LexisNexis PatentAdvisor ®, LexisNexis PatentOptimizer ®, LexisNexis ® PatentSight ® and LexisNexis TotalPatent One ® ) enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier and LexisNexis are part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details David Tucker Elsevier Communications, UK d.tucker@elsevier.com Company Website https://www.elsevier.com/

February 02, 2022 09:00 AM Eastern Standard Time

G Medical Innovations Holdings Ltd Announces $12 Million Private Placement

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced it has entered into a securities purchase agreement with a single institutional investor to issue, in a private placement, 2,400,000 ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,400,000 ordinary shares, at a purchase price of $5.00 per ordinary share (or pre-funded warrant) and associated warrant, for expected gross proceeds to the Company of approximately $12 million, before deducting placement agent fees and other offering expenses payable by the Company. The warrants will have an exercise price of $5.00 per ordinary share, will be exercisable immediately upon issuance, and will have a term of five years from the date of issuance. The closing of the private placement is expected to occur on or about February 2, 2022 subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for partial repayment of existing debt and working capital purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the private placement. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 15 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. INVESTOR RELATIONS CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 31, 2022 07:00 AM Eastern Standard Time

BitX Funding Triumphs With Record 2021 Results

BitX Funding

Fairfield, CT., January 24, 2022— BitX Funding, one of the most prominent alternative lenders in Southern Connecticut, announced a banner year for growth in 2021. Overall, revenue went up 10%, new users increased by 70%, impressions went up 300%, and business applications came in at a rate of 1,275% more than the previous year. Out of all the loans that BitX sold, Startup loans had the highest increase. “Our economy saw solid growth in small business lending and the startup loan category lead the way due to the great resignation”, said Todd Rowe, president of BitX Funding. “We continue to grow BitX revenue with support from internal sales, record marketing results, CT Innovations mentor support, and our raving fans. Our 2022 goals are to continue to build out our lending platform, grow our lender base, obtain our own lending facility, and drive client growth. Our goals are to increase revenue by 160%, have a 133% increase in units sold, and a loan amount increase of 200% in 2022.” Rowe continues to promote his company as a marketplace for small business loans, especially with young entrepreneurs. With one click, you can get a response to your loan request within 24 hours. That makes BitX Funding a partner you can trust in 2022. BitX Funding is an omnichannel marketplace for alternative small business loans and business insurance. BitX connects their clients with the right loan and lender from SBA 7a, start-up loans, short-term loans, mid-term loans to merchant cash advances and business lines of credit. BitX is where lenders compete for your business. Our top-rated lenders focus on real-life business data and cash flow, which means you can qualify for small business loans even if your credit score isn’t perfect. We care about small business and it’s our mission to secure the right funding when you need alternative small business loans within our small business loan marketplace. Contact Details BitX Funding Todd Rowe +1 203-763-1430 info@bitxfunding.com Company Website https://www.bitxfunding.com

January 27, 2022 01:05 PM Eastern Standard Time

2021 In Numbers: Mass. Cannabis Industry Testing Statistics

MCR Labs

Following another year of unpredictability, change, and challenges for the Massachusetts cannabis industry, MCR Labs is releasing data that may provide insight into the industry’s continued development. Here are MCR Labs’ most notable stats from Jan. 1, 2021 to Jan. 2, 2022: The Lab saw a 19% increase in samples submitted for testing, in comparison to 2020’s 38% increase. While flower sample submissions decreased by 8%, concentrate and vape submissions grew by 22%. The decrease in flower samples can be reasonably attributed to a regulatory change in batch size enacted in March. Solventless extract sample submission increased by 85%, and can most likely be attributed to the rising popularity of Hash Rosin. Hash Rosin submissions increased by 700%. Samples submitted to MCR in 2021 had a 92.3% pass rate for safety screens, up from 91.2% in 2020. For concentrate and vape samples, the pass rate decreased from 93.5% in 2020 to 91.8% in 2021, which can be attributed mostly to an increase in residual solvent failures. “As more and more facilities come online and employ hydrocarbon extraction techniques, we expect failures to remain the same or increase due to the extremely low regulatory limits,” said Jonathan Wani, Vice President of Business Development at MCR Labs. MCR Labs is licensed as an independent testing laboratory in both the Medical and Adult Use Marijuana programs, both overseen by the Massachusetts Cannabis Control Commission (CCC). The statistics provided here account for product samples submitted for compliance testing by cultivators and product manufacturers from the medical and adult-use programs, as well as home growers, patients, researchers, or curious consumers. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

January 27, 2022 09:00 AM Eastern Standard Time

2022 HIGH SCHOOL STUDENT WELLNESS AND TUTORING PLATFORM LAUNCHES AMID PANDEMIC: PROVIDES MUCH NEEDED STRESS REDUCTION, LEARNING STRATEGIES, AND LIFE SKILLS

Holistic Learning

Holistic Learning, founded by neuroscience, physiology and meditation experts Eli Marx-Kahn and Kush Patel, announces the launch of its platform on a mission to “help create a generation of purposeful, confident, and happy young people who are ready to take on the many issues our world faces. By integrating services in multiple domains – academics, wellness, and career development – we aim to help students find their unique paths in life.” The easy and fun to use platform incorporates timely and critical touchpoints for high school students: 1-on-1 tutoring, wellness & meditation courses, learning strategies, college counseling, career development, and life skills. Parents and educators see it as a valuable supplement providing their students with a number of individualized, self-select tools such as breathing exercises to reduce anxiety, STEM, English and writing tutoring, college application advice, and career seminars with professionals from dozens of fields. “We know that students who are healthy, happy, and stress-free are much more receptive to new knowledge. Holistic Learning equips them with the skills they need to manage their many obligations while prioritizing their own well-being,” states Co-Founder and Chief Wellness Officer Eli Marx-Kahn. Holistic Learning comes at a crucial time in education amid continued covid disruptions, isolation and uncertainty. According to “Education in the Pandemic, The Disparate Impacts of COVID-19 on America’s Student”: Emerging evidence shows that the pandemic has negatively affected academic growth, widening pre-existing disparities. In core subjects like math and reading, there are worrisome signs that in some grades students might be falling even further behind pre-pandemic expectations. Further, “The Mental Health of High School Students During the COVID-19 Pandemic” report states: “The American Psychological Association (APA) reports 81% of Gen Z teens (ages 13–17) have experienced more intense stress during the COVID-19 pandemic. Exercise time helps reduce mental health degradation (β3 = -0.153, p = 0.037). Many other factors such as gender, homework time, school time, pre-existing mental health issues, and therapy did not have a significant influence on mental health degradation. Analysis of freeform feedback identified the following three recurring themes: increased stress due homework (13.2%), social isolation or lack of social interactions (8.5%), and lack of support for mental wellbeing (12.3%)." "I am very interested in how the brain works and am passionate about using my knowledge of neuroscience to make studying more fun and manageable for students at every point in their education,” shares Kush Patel, Co-Founder and Chief Learning Officer at Holistic Learning. “Throughout my college years, I helped hundreds of students achieve their academic aspirations through my role as a tutor, peer mentor to students with disabilities, study group leader, and learning strategist. I enjoy creating learning strategy content for students as well as designing a holistic tutoring curriculum to ensure that true and meaningful understanding is achieved." Based on frequency of tutoring desired, tiered subscriptions are available at www.holisticlearning.co, and are priced well below standalone tutoring and counseling programs. Sliding scale scholarship opportunities are available for low income families, by inquiring at info@holisticlearning.co. “Holistic Learning is committed to accessibility and equality of access,” states Marx-Kahn. “It was created as an online space designed to meet the needs that high school alone cannot meet, to help students grow, and to help them visualize their path towards a meaningful and fulfilling future. The Pandemic has made the need for a service like Holistic Learning greater than ever.” ### Holistic Learning is an online learning platform designed to help high school students achieve academic success as well as personal and professional growth. It integrates a range of timely and critical services including 1-on-1 tutoring, learning strategies, meditation & wellness courses, college counseling, life skills, and career seminars. Parents and educators see it as a valuable supplement providing their students with the tools to live healthy, happy, and stress-free lives. www.holisticlearning.co Contact Details AnnMarie Fauske +1 630-880-3485 outreach@holisticlearning.co

January 25, 2022 09:00 AM Central Standard Time

Video Image

G Medical Innovations Joins Forces with Serology Covid Testing to Support Safer Classroom Learning in California School Districts Amid Omicron Variant Surge

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (“G Medical” or the "Company"), a Telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced it has formed an agreement with Serology Covid Testing to provide zero-cost COVID-19 testing to students, families, and school employees across the State of California. G Medical’s wholly owned subsidiary, G Medical Tests and Services, Inc., will provide end-to-end testing services including setup; certified medical staff; testing kits, supplies and necessary personal protective equipment; and an online patient portal to easily administer tests and provide digital certified lab results. "It's an honor for us to partner with Serology Covid Testing and collaborate with educators and public health officials across the State of California to help keep children and their families safe," said Dr. Yacov Geva, President and CEO of G Medical. "Testing programs like these give schools the freedom and flexibility they need to halt transmission chains and minimize disturbance to all of the vital activities that take place in school communities daily." As phase one of the agreement, the co-branded testing venture includes contracts with multiple private and public institutions enabling more than 5,000 students (not including families and faculty) to be tested weekly. On average, G Medical expects to collect an average of $197.88 per patient encounter, which could amount to more than $1,000,000 in gross revenue per week. The agreement stems from a shared commitment to "keeping schools open" by assisting in the recovery of the U.S. teaching market, reducing educational staff turnover, and assisting in the reversal of the pandemic's disproportionate impact on the education-sector workforce. As the Omicron variant continues to escalate, California school systems are facing teacher shortages, lack of rapid testing options, and the daunting task of keeping schools open for its students statewide. "We are thrilled to establish this long-term partnership with G Medical. This relationship is especially meaningful to us because our testing services are now endorsed by a pioneering healthcare company," said Caroline Grotewiel, CEO of Serology Covid Testing. "As a result of our collaborative efforts, we can help students, educators, and their families have more peace of mind, and our classrooms will be more conducive to in-person learning.” Communities across the country have turned to COVID-19 testing to monitor the virus as more vaccine trials for people under the age of 16 are just getting started, and efforts to track and mitigate viral spread remain critical. Together, the companies will offer on-site Rapid Antigen Testing with confirmatory PCR tests, as recommended by the Centers for Disease Control (CDC). “Hundreds of students and staff have tested positive for the virus since schools reopened after the holidays, forcing some districts to switch to remote learning just days after reopening,” added Andrew Benavente, Vice President of Serology Covid Testing. “By implementing these free testing services at their doorstep, we can empower students and teaching staff to return to school as quickly and safely as possible after a potential exposure.” "G Medical has long been at the forefront of medical devices, offering remote patient monitoring tools to help keep patients healthy. We're excited to expand our portfolio to offer COVID-19 testing options that help to detect the virus early and enable individuals, businesses, and schools to take appropriate action to prevent further spread in the community," concluded Geva. If you are interested in offering your school free on-site COVID-19 testing services, please contact Andrew Benavente at Serology Covid Testing; +1 310-747-5473; Andrew.m@Serology-Testing.com. About Serology Covid Testing Serology Covid Testing is a consulting group, distributor, and executor of advanced testing that specializes in bringing new health and wellness solutions and technologies to market. With over 20 years of experience, relationships, and well-established partnerships, we participate in implementing innovative technologies within our network of clinics in addition to bringing full-service testing services to businesses, schools, and events Nationwide. Serology Covid Testing is dedicated to meeting the urgent need for COVID-19 testing by utilizing cutting-edge technology, FDA or EUA approved assays, and highly trained laboratory professionals to deliver rapid results of unwavering quality. To learn more, visit: https://www.serology-testing.com/ About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the agreement with Serology Covid Testing, providing end-to-end testing services including setup; certified medical staff; testing kits, supplies and necessary personal protective equipment; and an online patient portal to easily administer tests and provide digital certified lab results, the number of COVID-19 testing to be conducted and the timing thereof, and anticipated gross revenue. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. INVESTOR RELATIONS AT GMEDICAL CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com SEROLOGY COVID TESTING CONTACT: Serology Covid Testing Andrew Benavente +1 310-747-5473 Andrew.m@Serology-Testing.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 25, 2022 04:03 AM Eastern Standard Time

METER Group Introduces the ROS 1 Moisture Analyzer for Food and Pharma

METER Group, Inc.

METER Group today introduced the ROS 1 Moisture Analyzer, a revolutionary, modern, easy-to-use, automated reference method for moisture content analysis. The ROS 1 generates reference-quality data with ease-of-use comparable to halogen moisture balances, without the time and manual effort of drying ovens or the complexity and chemicals of Karl Fischer Titration (KF Titration). “Food and pharma manufacturers rely on moisture content measurements to control their processes and comply with labelling and potency requirements,” said Takuya Ohki, VP, METER Group. “The most accurate moisture content methods are incredibly complex or inefficient. Faster methods lack precision and produce questionable results. “We developed the ROS 1 to address this gap. It’s fast, precise, intuitive, and handles every detail automatically. It combines the best of all methods without their shortcomings.” Water content affects storage stability, appearance, texture, and taste, as well as other physicochemical characteristics of food, and is legally stipulated as well. The ROS 1 Moisture Analyzer determines moisture content from as many as nine samples in 40 minutes with reference-method precision. With an element positioned millimeters from the sample, it precisely heats each sample while cycling them across a highly accurate scale. Throughout the process, it records temperature, weight, and time, then generates an exact drying curve for each sample. Karl Fischer titration is complex and time-consuming. It uses hazardous chemicals and requires a skilled operator. Oven loss-on-drying requires significant hands-on time and often requires hours to complete. Like these reference methods, the ROS 1 is sample agnostic, using intelligent algorithms to recognize the perfect parameters for any substance without having to research test setup. Leveraging automation, it has the potential to save businesses and scientists hundreds of hours each month. “The ROS 1 brings a new level of efficiency and accuracy to food and pharma production, and delivers unprecedented precision and simplicity to workflows,” added Ohki. “Interaction with samples is minimal; the machine does the work, virtually eliminating the risk of human error or fudged data.” The ROS 1 uncovers a depth of real-time, actionable insights that moisture balances and ovens cannot detect, without the time and effort usually required. It dries to a standard, so measurements have real context and meaning. Titration takes a great deal of expertise and is usually only performed by experienced food scientists and other highly skilled employees. It also requires use and disposal of potentially dangerous chemicals. “By-the-book oven methods require hours of repetitive labor and require constant attention from operators. I’ve met manufacturers that had to run an additional lab shift just to manage oven samples. Conversely, the ROS 1 helps you meet industry regulations while automating rote tasks, freeing scientists to focus their attention on more important, profitable work,” added Ohki. Ovens are also problematic, often requiring several hours to dry samples, and additional time spent waiting for samples to cool in desiccators. Other methods that tout speed lack the precision outputs that food and pharma manufacturers require. “Many people who make moisture content measurements neither understand nor care how difficult it is to get precise, reliable results from existing methods,” says Ohki, “But inaccurate measurements have a big impact on the bottom line. For people who understand moisture, this innovation will immediately resonate. Others will get interested when they see what they can now do. “With the ROS 1, METER Group has brought to market the first and only moisture content analyzer device to offer precision of reference methods, the simplicity of an oven, and speed comparable to a moisture balance.” About METER Group METER Group, a Decagon and UMS combined company, delivers real-time, high-resolution data that fuels production and processes for the food quality, environmental research, urban and agriculture sectors. Through the power of its employees, METER combines science, engineering, and design expertise to turn physical measurements into useful information. Learn more at www.metergroup.com. Contact Details JMRConnect Mostafa Razzak +1 202-904-2048 m.razzak@jmrconnect.net

January 20, 2022 09:00 AM Eastern Standard Time

BirchAI RAISES $3.1M SEED ROUND FOR HEALTHCARE CUSTOMER SUPPORT PLATFORM POWERED BY CUTTING EDGE AI

BirchAI

BirchAI, the leading AI platform for healthcare customer support, today announced $3.1 million in seed financing led by the AI-focused venture capital firm Radical Ventures. Leveraging groundbreaking natural language processing (NLP) capabilities, the company is set to significantly improve efficiency in the healthcare sector by automating resource-intensive aspects of customer support including the summarization, classification and analysis of customer calls. BirchAI is a spinout from the Allen Institute for AI (AI2), one of the world’s leading AI research organizations. In addition to Radical and AI2, Flare Capital Partners and WRF Capital are participating in the funding round. In many sub-sectors of healthcare, front-line phone-based customer support teams are staffed by clinically or otherwise highly trained employees. The industry already faced the retirement bulge of Baby Boomer staff aging out of these roles, and the pandemic has made finding qualified support staff a pressing issue for the medical device, pharmaceutical and health insurance industries. Using state-of-the-art AI, BirchAI is tackling this costly dilemma by automating after-call work for large enterprises, while simultaneously capturing the data from these calls to provide customer insights. BirchAI was founded by Kevin Terrell, Sumant Kawale, and Yinhan Liu. The team has worked together in AI applications before starting BirchAI, and brings together deep expertise in cutting-edge AI, healthcare, and enterprise AI deployment. “Many calls in the healthcare industry are complex, lengthy, and costly, due to significant documentation requirements,” said Kevin Terrell, co-founder and CEO of BirchAI. “Our initial focus is on complex calls, which generate over $10 billion in annual costs to the healthcare system. With BirchAI, companies will make it easier for their employees to document and analyze calls. Our platform lowers costs and improves the quality of the customer and employee experiences.” BirchAI’s world-class AI team is led by its co-founder and CTO Yinhan Liu. Prior to BirchAI Yinhan was a star researcher at Facebook AI Research (FAIR), where she was lead author on some of Facebook’s most important work in NLP, including the well-known RoBERTa and BART papers. Yinhan is responsible for building BirchAI’s NLP technology from the ground up, allowing for accurate language documentation and summarization at a greater scale. “The BirchAI team brings extraordinary technological depth and industry experience to tackling a very real problem facing the healthcare industry,” said Radical Ventures Partner Rob Toews, who has joined the BirchAI board. “The BirchAI NLP platform goes beyond delivering cost savings and efficiencies. AI technology of this nature also unlocks insights that can fuel strategic product and business decisions for its customers.” WHY BIRCH.AI MATTERS Leading-edge NLP can now be applied to the healthcare industry’s most costly customer support challenges. Integration allows for a simple platform deployment so there’s no disruption to critical business and customer service. The platform detects trends well ahead of traditional analysis allowing for an earlier warning system if a potential harmful pattern appears. Automation of call handling lowers After Call Work on average by 50 to 75%, saving time and money while improving employee engagement and customer satisfaction. The additional funding will accelerate the Birch.ai team’s growth, address its customer backlog, and allow the company to advance its AI platform. BirchAI is currently working with multiple Fortune 500 healthcare companies, including a payer and a leading medical device firm. The company is also focusing on growing its client base in the pharmaceutical sector to help with the pharmacovigilance process. “BirchAI’s intelligent automation platform transforms and digitizes some of the most complex and manual call-based workflows in healthcare, enabling customer support teams to provide higher-quality patient care guided by new clinical insight, while also reducing the cost of this care,” said Parth Desai at Flare Capital Partners. “Flare Capital is excited to support the BirchAI team on their mission.” For more information about BirchAI, please visit www.birch.ai or follow Birch_ai on Twitter and LinkedIn. About BirchAI: BirchAI was founded in 2020 by leading experts in artificial intelligence, process improvement and the healthcare industry. Backed by the Allen Institute of AI (AI2), Birch.ai provides a solution to tackle fundamental problems within our healthcare system through AI and natural language processing. About Radical Ventures: Radical Ventures is an early-stage venture capital firm investing in people applying artificial intelligence to shape the future of how we live, work and play. From healthcare and financial services to infrastructure and manufacturing, Radical partners with entrepreneurs who understand the transformational power of AI. Learn more at www.radical.vc. About AI2: AI2 was founded in 2014 with the singular focus of conducting high-impact research and engineering in the field of artificial intelligence, all for the common good. AI2 is the creation of Paul Allen, Microsoft co-founder, and is led by Dr. Oren Etzioni, a leading researcher in the field of AI. AI2 employs more than 100 top-notch researchers and engineers from across the globe. AI2 prides itself on the diversity and collaboration of our team and takes a results-oriented approach to complex challenges in AI. Learn more at allenai.org. Contact Details Forrest Carman +1 206-859-3118 forrestc@owenmedia.com Company Website https://birch.ai/

January 19, 2022 09:00 AM Pacific Standard Time

1 ... 161 162 163 164 165 ... 211